Advertisement
Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ANR.AX) Stock Competitors & Peer Comparison

See (ANR.AX) competitors and their performances in Stock Market.

ANR.AXASX
HealthcareBiotechnology
$0.01
$0.00(0.00%)
Australian Market opens in 50h 1m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ANR.AXA$0.01+0.00%2.1M-1.25-A$0.01N/A
CSL.AXA$116.13-1.29%55B12.35A$9.30+3.71%
TLX.AXA$16.20+3.32%5.2B-553.23-A$0.03N/A
MSB.AXA$1.95-6.39%2.4B-12.68-A$0.15N/A
NEU.AXA$16.60+30.09%1.5B51.94A$0.23N/A
PYC.AXA$1.66+8.14%895M-33.66-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M-60.00-A$0.01N/A
CUV.AXA$10.34+2.89%503.6M15.51A$0.64+0.50%
RAC.AXA$2.21-5.96%433.3M-106.76-A$0.02N/A
SPL.AXA$0.70+1.45%292.5M110.32A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ANR.AX vs CSL.AX Comparison July 2026

ANR.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ANR.AX stands at 2.1M. In comparison, CSL.AX has a market cap of 55B. Regarding current trading prices, ANR.AX is priced at A$0.01, while CSL.AX trades at A$116.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ANR.AX currently has a P/E ratio of -1.25, whereas CSL.AX's P/E ratio is 12.35. In terms of profitability, ANR.AX's ROE is -1.09%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, ANR.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ANR.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions